Tiziana Life Sciences (TLSA, Financial) has taken a significant step in its Phase 2 trial by initiating patient dosing at a fourth clinical site, the University of Massachusetts. This trial is focused on evaluating the efficacy of intranasal foralumab in individuals with non-active secondary progressive multiple sclerosis (na-SPMS).
The inclusion of the University of Massachusetts adds to the growing list of prestigious institutions participating in this clinical study. Brigham and Women’s Hospital, the Yale Multiple Sclerosis Center, and Johns Hopkins University's Autoimmunity Center of Excellence are already involved in actively dosing participants for this trial.
This expansion underscores Tiziana Life Sciences' commitment to advancing potential treatments for multiple sclerosis through strategic collaborations with top research centers.
